Screener
ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q1 2025 earnings
Reported May 15, 2025 · Before market open
Revenue$10.0MBeat by $8.8M
EPS-$0.80Beat by $0.31
Revenue estimate$1.3M
EPS estimate-$1.11
Next report
Nov 12, 2026 (in 2 months)Revenue estimate$1.0M
EPS estimate-$1.22
Versus estimates
Revenue
Q2 2026$1.0MMiss by $14.0M
Q1 2025$10.0MBeat by $8.8M
Diluted EPS
FAQ
- When did ProShares UltraPro Short NASDAQ Biotechnology report Q1 2025 earnings?
- ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q1 2025 earnings on May 15, 2025 before market open.
- What were ProShares UltraPro Short NASDAQ Biotechnology's Q1 2025 revenue and EPS?
- ProShares UltraPro Short NASDAQ Biotechnology reported revenue of $10.0M and eps of $-0.80 for Q1 2025.
- Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q1 2025?
- Revenue beat the consensus estimate of $1.3M by $8.8M. EPS beat the consensus estimate of $-1.11 by $0.31.
- Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q1 2025 SEC filings?
- You can read the 8-K earnings release (0001104659-25-048948) and the 10-Q periodic report (0001558370-25-007803) directly on SEC EDGAR. The filing index links above go to sec.gov.
